

# Gastrointestinal (GI) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



**NEOADJUVANT**

**A022104/Janus Trial**  
(Triplet vs. double chemo)

Coord: A. Luna  
PI: Dr. Zell  
Accrual: 6/15

**CCTG-CO32**  
(NEO-RT trial)  
**(opened 4/29/24)**

Coord: P. Yang  
PI: Dr. Zell  
Accrual: 2/5

**EA2201**  
(Nivo + lpi + radiation)

**Suspended 5/9/23**

Coord: K. Ghio  
PI: Dr. Valerin  
Accrual: 0/3

**UCI 21-67**  
(Epcadostat + short course radiation + chemo)

PI: Dr. Valerin  
Pending activation

**ADJUVANT**

**NRG-GI008/CIRCULATE**  
(ctDNA guided tx)

**(opened 9/14/22)**

Coord: A. Luna  
PI: Dr. Zell  
Accrual: 2/5

**INTRA-OPERATIVE**

**UCI 20-163**  
(SOC vs CG-100 Intraluminal)  
**(opened 10/11/24)**

Coord: M. Nguyen  
PI: Dr. Carmichael  
Accrual: 2/10  
Bypass Device

**MOLECULAR FAILURE**

**UCI 20-43**  
(TAS102 + irinotecan)

Coord: K. Ghio  
PI: Dr. Dayyani  
Accrual: 5/11



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

### 1L METASTATIC

### 2L METASTATIC

### 3L METASTATIC

#### A022101

(at least 4 months of chemo once metastatic disease is confirmed)

**(opened 12/13/23)**

Coord: A. Luna

PI: Dr. Eng  
Accrual: 0/2

UCI 23-228  
(TAK-676 +/- pembrolizumab)  
**(opened 11/5/24)**

Coord: B. Huynh

PI: Dr. Nabar  
Accrual: 0/5

UCI 21-39  
(Pembro + TATE)

Coord: LM Aguilar

PI: Dr. Abi-Jaoudeh  
Accrual: 19/30



Newly Diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Advanced/Metastatic

ECOG-EA2176

(Nivolumab + Carboplatin +  
Paclitaxel)

Coord: J. Koff

PI: Dr. Valerin

Accrual: 4/5

## Neoadjuvant

**UCI 21-191**  
(SOC therapy with ctDNA testing)

Coord: A. Luna  
PI: Dr. Dayyani  
Pending activation

## ESCC

**UCI 24-77**  
(I-DXd)

Coord: TBD  
PI: Dr. Dayyani  
Pending activation

## Newly Diagnosed Metastatic

**UCI 20-87**  
(V Paclitaxel + IV 5-FU + IV leucovorin + IP paclitaxel)

Coord: LM Aguilar  
PI: Dr. Senthil  
Accrual: 27/40

**A022102**  
(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 7/14

**EA2183**  
(SOC + XRT)  
**(reopened 6/13/24)**

Coord: J. Koff  
PI: Dr. Hong  
Accrual: 0/7

**UCI 21-193**  
(FGFR inhibitor + mFOLFOX6 + antiPD-L1 (nivolumab))  
**(Suspended 10/1/24)**

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 1/12

**UCI 21-10**  
(FOLFOX + nivo + Bispecific antibody (anti-CLDN18.2 + anti-4-1BB))

Coord: K. Ghio/J. Koff  
PI: Dr. Dayyani  
Accrual: 13/17

## Recurrent

**UCI 23-78**  
(EGFR and MET-directed antibody)  
**(opened 3/1/24)**

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 0/3

**UCI 23-109**  
(Disitamab Vedotin + Tucatinib)  
**(opened 4/25/24)**

Coord: M. Nguyen  
PI: Dr. Dayyani  
Accrual: 2/10

**UCI 23-200**  
(AZD0901)  
**(opened 7/24/24)**

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 2/10

**UCI 23-173**  
(ICI in ARID1a Mu)  
Coord: TBD  
PI: Dr. Dayyani  
Pending activation

**UCI 16-94**  
(Tirapazamine, Nivolumab)

Coord: LM Aguilar  
PI: Dr. Abi-Jaoudeh  
Accrual: 28/40

**UCI 22-51**  
**(opened 3/7/24)**  
(ASP2138)

Coord: N. Ferrand  
PI: Dr. Dayyani  
Accrual: 11/20

**UCI 24-49**  
**(opened 10/22/24)**  
(Beamion BCGC-1: Oral Zongertinib + Trastuzumab Deruxtecan or + Trastuzumab Emtansine)

Coord: M. Bauk  
PI: Dr. Dayyani  
Accrual: 0/10



■ Open to Accrual    
 ■ Low Accruing    
 ■ Pending Activation/Suspended

## HER-2

**ETCTN-10358/DASH**  
 (DS8201a + AZD6738)  
(opened 5/5/23)  
 Coord: M. Nguyen  
 PI: Dr. Dayyani  
 Accrual: 2/3

**ETCTN-10495**  
 (DS-8201a + Neratinib)  
(Suspended 11/5/24)  
 Coord: M. Nguyen  
 PI: Dr. Dayyani  
 Accrual: 1/7

**UCI 20-67**  
 (Anti-PD-1 DF1001  
 (monotherapy or  
 combination therapy)  
 Coord: M. Nguyen  
 PI: Dr. Valerin  
 Accrual: 18/29

## BRAF

## KRAS

**UCI 24-65**  
 (FMC-376 in KRASG12C)  
(opened 11/4/24)  
 Coord: P. Yang  
 PI: Dr. Dayyani  
 Accrual: 0/5

## EGFR

**UCI 22-171**  
 (Anti-PD-1 +/- DF9001)  
(opened 7/17/24)  
 Coord: M. Nguyen  
 PI: Dr. Valerin  
 Accrual: 4/25

## CLDN18.2

**UCI 22-51**  
 (ASP2138)  
(opened 3/7/24)  
 Coord: N. Ferrand  
 PI: Dr. Dayyani  
 Accrual: 9/20

**UCI 23-200**  
 (AZD0901)  
(opened 7/24/24)  
 Coord: J. Koff  
 PI: Dr. Dayyani  
 Accrual: 2/10



**UCI 23-85**  
(BA3182 + (EPCAM)/CD3  
Antibody)

**(opened 9/19/24)** Coord:  
J. Balangue

PI: Dr. Valerin  
Accrual: 0/5

**UCI 21-146**  
(Anti-Tissue Factor  
monoclonal antibody-  
BCNvcMMAE conjugate)

**(Suspended 5/6/24)**

Coord: C. Kang  
PI: Dr. Dayyani  
Accrual: 5/11

**ETCTN-10579**  
(ZEN003694 (ZEN-3694)  
+ capecitabine)

**(opened 10/27/23)**

Coord: P. Yang  
PI: Dr. FC Lee  
Accrual: 2/4

**UCI 23-197**  
(DF6215)

**(opened 7/12/24)**

Coord: N. Arechiga  
Accrual: 1/5

**UCI 22-26**  
(Androgen and  
glucocorticoid receptor  
antagonist)

Coord: N. Ferrand

PI: Dr. Dayyani  
Accrual: 8/12



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

**UCI 03-03**

(Immunologic response analysis)

Coord: B. Sanchez  
PI: Dr. Imagawa  
Accrual: 336/400

**UCI 23-29**

(Electroacupuncture in symptom management after CRS/HIPEC)

**(opened 8/8/24)**  
PI: Dr. Eng  
Accrual: 0/15

**UCI 20-04**

(Tissue Collection)

Coord: B. Sanchez  
PI: Dr. Dayyani  
Accrual: 99/130

**UCI 22-55**

(ID GenomeSig for HomoRecomboDeficiency inPC &Mismatch RepairDeficiency in Microsatellite Instable CC)

PI: Dr. Pannunzio/Dr. Valerin  
Pending activation